Paper2462467
Modification of tumor cells by a low dose of Newcastle disease virus. II. Augmented tumor-specific T cell response as a result of CD4+ and CD8+ immune T cell cooperation.
Schild H and 2 others. Cancer Immunol Immunother, 1989. Cited by 45 papers, by iCite.
Cite this record
ConductScience Library. Modification of tumor cells by a low dose of Newcastle disease virus. II. Augmented tumor-specific T cell response as a result of CD4+ and CD8+ immune T cell cooperation. Papers, record 2462467. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/2462467
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Modification of tumor cells by a low dose of Newcastle disease virus. II. Augmented tumor-specific T cell response as a result of CD4+ and CD8+ immune T cell cooperation.
- PubMed
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Cell Transformation, Viral | Major topic |
| Cytotoxicity, Immunologic | Major topic |
| Lymphocyte Cooperation | Major topic |
| Lymphoma | Major topic |
| Newcastle disease virus | Major topic |
| T-Lymphocytes | Major topic |
| Animals | |
| Antigens, Differentiation, T-Lymphocyte | |
| Epitopes | |
| Interleukin-2 | |
| Mice | |
| Mice, Inbred DBA | |
| Mice, Nude | |
| Phenotype | |
| Time Factors | |
| Viral Vaccines |
Source PubMed
References25
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 92181 | Virus augmentation of the antigenicity of tumor cell extracts. | Adv Cancer Res | 1979 | https://conductscience.org/library/papers/92181 | PubMed |
| 2 | 6172493 | Interleukin 2 is not sufficient as helper component for the activation of cytotoxic T lymphocytes but synergizes with a late helper effect that is provided by irradiated I-region-incompatible stimulator cells. | J Immunol | 1982 | https://conductscience.org/library/papers/6172493 | PubMed |
| 3 | 3155458 | T-T cell interaction in the induction of delayed-type hypersensitivity (DTH) responses: vaccinia virus-reactive helper T cell activity involved in enhanced in vivo induction of DTH responses and its application to augmentation of tumor-specific DTH responses. | J Immunol | 1985 | https://conductscience.org/library/papers/3155458 | PubMed |
| 4 | 92180 | Viral xenogenization of intact tumor cells. | Adv Cancer Res | 1979 | https://conductscience.org/library/papers/92180 | PubMed |
| 5 | 6159417 | IgG or IgM monoclonal antibodies reactive with different determinants on the molecular complex bearing Lyt 2 antigen block T cell-mediated cytolysis in the absence of complement. | J Immunol | 1980 | https://conductscience.org/library/papers/6159417 | PubMed |
| 6 | 3156935 | A rapid colorimetric assay for the determination of IL-2-producing helper T cell frequencies. | J Immunol Methods | 1985 | https://conductscience.org/library/papers/3156935 | PubMed |
| 7 | 3919312 | Expression of interleukin-2 receptors as a differentiation marker on intrathymic stem cells. | Nature | 1985 | https://conductscience.org/library/papers/3919312 | PubMed |
| 8 | 6415170 | Characterization of the murine T cell surface molecule, designated L3T4, identified by monoclonal antibody GK1.5: similarity of L3T4 to the human Leu-3/T4 molecule. | J Immunol | 1983 | https://conductscience.org/library/papers/6415170 | PubMed |
| 9 | 6333273 | Resistance of metastatic tumor variants to tumor-specific cytotoxic T-lymphocytes not due to defects in expression of restricting major histocompatibility complex molecules in murine cells. | Cancer Res | 1984 | https://conductscience.org/library/papers/6333273 | PubMed |
| 10 | 6150440 | Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo. | Nature | 1984 | https://conductscience.org/library/papers/6150440 | PubMed |
| 11 | 2785093 | Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. III. Postoperative activation of tumor-specific CTLP from mice with metastases requires stimulation with the specific antigen plus additional signals. | Invasion Metastasis | 1989 | https://conductscience.org/library/papers/2785093 | PubMed |
| 12 | 6546769 | Newcastle disease virus: the effect of monoclonal antibody in the overlay on virus penetration and the immunoselection of variants. | J Gen Virol | 1984 | https://conductscience.org/library/papers/6546769 | PubMed |
| 13 | 3005417 | Helper T cells against tumor-associated antigens (TAA): preferential induction of helper T cell activities involved in anti-TAA cytotoxic T lymphocyte and antibody responses. | J Immunol | 1986 | https://conductscience.org/library/papers/3005417 | PubMed |
| 14 | 307029 | T cell growth factor: parameters of production and a quantitative microassay for activity. | J Immunol | 1978 | https://conductscience.org/library/papers/307029 | PubMed |
| 15 | 2970967 | Modification of tumor cells by a low dose of Newcastle disease virus. Augmentation of the tumor-specific T cell response in the absence of an anti-viral response. | Eur J Immunol | 1988 | https://conductscience.org/library/papers/2970967 | PubMed |
| 16 | 6606682 | Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. | J Immunol Methods | 1983 | https://conductscience.org/library/papers/6606682 | PubMed |
| 17 | 3514798 | The biological modification of tumor cells as a means of inducing their regression: an overview. | J Biol Response Mod | 1986 | https://conductscience.org/library/papers/3514798 | PubMed |
| 18 | 25290399 | Strategies for cell-mediated immunotherapy of cancer: killing or help? | Immunol Today | 1986 | https://conductscience.org/library/papers/25290399 | PubMed |
| 19 | 3930610 | Alloantigen-activated lymphocytes from mice bearing a spontaneous "nonimmunogenic" adenocarcinoma inhibit its growth in vivo by recruiting host immunoreactivity. | J Immunol | 1985 | https://conductscience.org/library/papers/3930610 | PubMed |
| 20 | 2938736 | The augmentation of tumor-specific immunity by virus help. III. Enhanced generation of tumor-specific Lyt-1+2- T cells is responsible for augmented tumor immunity in vivo. | Cancer Immunol Immunother | 1986 | https://conductscience.org/library/papers/2938736 | PubMed |
Cited by25
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 45 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42699700 | Newcastle Disease Virus - Induced Interferons Regulate PD-L1 and MICA Expression in Human Tumor and Normal Cells. | Immunotargets Ther | 2026 | https://conductscience.org/library/papers/42699700 | PubMed |
| 39062070 | Newcastle Disease Virus Virotherapy: Unveiling Oncolytic Efficacy and Immunomodulation. | Biomedicines | 2024 | https://conductscience.org/library/papers/39062070 | PubMed |
| 37720338 | Papaverine Enhances the Oncolytic Effects of Newcastle Disease Virus on Breast Cancer In Vitro and In Vivo. | Int J Microbiol | 2023 | https://conductscience.org/library/papers/37720338 | PubMed |
| 36361831 | Counteracting Immunosuppression in the Tumor Microenvironment by Oncolytic Newcastle Disease Virus and Cellular Immunotherapy. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/36361831 | PubMed |
| 35860357 | Development of Molecular Mechanisms and Their Application on Oncolytic Newcastle Disease Virus in Cancer Therapy. | Front Mol Biosci | 2022 | https://conductscience.org/library/papers/35860357 | PubMed |
| 35327364 | Molecular Mechanisms of Anti-Neoplastic and Immune Stimulatory Properties of Oncolytic Newcastle Disease Virus. | Biomedicines | 2022 | https://conductscience.org/library/papers/35327364 | PubMed |
| 34209981 | Combinatorial Approaches for Cancer Treatment Using Oncolytic Viruses: Projecting the Perspectives through Clinical Trials Outcomes. | Viruses | 2021 | https://conductscience.org/library/papers/34209981 | PubMed |
| 33967605 | Advances in the Study of Antitumour Immunotherapy for Newcastle Disease Virus. | Int J Med Sci | 2021 | https://conductscience.org/library/papers/33967605 | PubMed |
| 33805626 | Less Can Be More: The Hormesis Theory of Stress Adaptation in the Global Biosphere and Its Implications. | Biomedicines | 2021 | https://conductscience.org/library/papers/33805626 | PubMed |
| 32188078 | Cancer Vaccines and Oncolytic Viruses Exert Profoundly Lower Side Effects in Cancer Patients than Other Systemic Therapies: A Comparative Analysis. | Biomedicines | 2020 | https://conductscience.org/library/papers/32188078 | PubMed |
| 32155856 | New Insights into Mechanisms of Long-term Protective Anti-tumor Immunity Induced by Cancer Vaccines Modified by Virus Infection. | Biomedicines | 2020 | https://conductscience.org/library/papers/32155856 | PubMed |
| 31480379 | Breaking Therapy Resistance: An Update on Oncolytic Newcastle Disease Virus for Improvements of Cancer Therapy. | Biomedicines | 2019 | https://conductscience.org/library/papers/31480379 | PubMed |
| 31338417 | Tumor Cells Modified with Newcastle Disease Virus Expressing IL-24 as a Cancer Vaccine. | Mol Ther Oncolytics | 2019 | https://conductscience.org/library/papers/31338417 | PubMed |
| 28536382 | Fifty Years of Clinical Application of Newcastle Disease Virus: Time to Celebrate! | Biomedicines | 2016 | https://conductscience.org/library/papers/28536382 | PubMed |
| 28531117 | Immunobiology of Newcastle Disease Virus and Its Use for Prophylactic Vaccination in Poultry and as Adjuvant for Therapeutic Vaccination in Cancer Patients. | Int J Mol Sci | 2017 | https://conductscience.org/library/papers/28531117 | PubMed |
| 23365495 | An overview on the development of newcastle disease virus as an anti-cancer therapy. | Malays J Med Sci | 2003 | https://conductscience.org/library/papers/23365495 | PubMed |
| 22131816 | Safety and clinical usage of newcastle disease virus in cancer therapy. | J Biomed Biotechnol | 2011 | https://conductscience.org/library/papers/22131816 | PubMed |
| 19565923 | Newcastle disease virus: a promising vector for viral therapy, immune therapy, and gene therapy of cancer. | Methods Mol Biol | 2009 | https://conductscience.org/library/papers/19565923 | PubMed |
| 8690751 | Preferential cytotoxic effect of Newcastle disease virus on lymphoma cells. | J Cancer Res Clin Oncol | 1996 | https://conductscience.org/library/papers/8690751 | PubMed |
| 7642685 | Biotherapy of cancer. Perspectives of immunotherapy and gene therapy. | J Cancer Res Clin Oncol | 1995 | https://conductscience.org/library/papers/7642685 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/2462467
GET https://conductscience.org/api/papers/v1/2462467/references?page=2